Last updated on January 2019

A Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation


Brief description of study

The purpose of this study is to evaluate the safety of ivacaftor treatment, and PK of ivacaftor and metabolites in subjects with cystic fibrosis (CF) who are <24 months of age at treatment initiation and have a CF transmembrane conductance regulator (CFTR) gene gating mutation

Clinical Study Identifier: NCT02725567

Find a site near you

Start Over

Medical Information

Birmingham, AL United States
  Connect »

Medical Information

Palo Alto, CA United States
  Connect »

Medical Information

Atlanta, GA United States
  Connect »

Medical Information

Chicago, IL United States
  Connect »

Medical Information

Indianapolis, IN United States
  Connect »

Medical Information

Baltimore, MD United States
  Connect »

Medical Information

Boston, MA United States
  Connect »

Medical Information

Kansas City, MO United States
  Connect »

Medical Information

Columbus, OH United States
  Connect »

Medical Information

Philadelphia, PA United States
  Connect »

Medical Information

Houston, TX United States
  Connect »

Medical Information

Seattle, WA United States
  Connect »

Medical Information

Madison, WI United States
  Connect »

Medical Information

Parkville, Australia
  Connect »

Medical Information

South Brisbane, Australia
  Connect »

Medical Information

Edinburgh, United Kingdom
  Connect »

Medical Information

Leicester, United Kingdom
  Connect »

Medical Information

London, United Kingdom
  Connect »

Medical Information

Manchester, United Kingdom
  Connect »

Medical Information

Oxford, United Kingdom
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.